"We are proud to showcase this data at DDW to leading gastroenterologists and researchers to continue to reiterate the benefits of rifaximin for patients with
More From BioPortfolio on "Salix Presents Rifaximin Phase 3 Study Results for Irritable Bowel Syndrome with Diarrhea at ..."